Advanced Lung Disease Transplant Services

Adult Cystic Fibrosis (CF)

As a nationally recognized center of excellence Stanford’s Adult Cystic Fibrosis Program aims to have the best CF survival outcomes in the country and the world.  We offer exceptional care through innovative treatments and rapid access to specialists trained to deal with the most critical cystic fibrosis issues.

Stanford’s Adult Cystic Fibrosis Program Highlights

Superior patient care and services.  With the largest adult cystic fibrosis center in California, our program promotes longevity through a broad range of services including nutritional, emotional, psychological, and social support, as well as access to cutting edge clinical trials and transplant services.  Benefits include:

  • A large multidisciplinary team including gastrointestinal, CF liver transplantation, general surgery, endocrinology, ear, nose, and throat, infection disease specialists, reproductive specialists, and interventional radiology
  • Dedicated follow up care with a commitment to see patients a minimum of 4 times per year
  • Access to Stanford’s transplant program for early identification of those who would benefit from transplant evaluation
  • Monthly involvement with a Cystic Fibrosis Parent Advisory Board to address parent/patient issues
  • Continuous collaboration with Lucile Packard’s pediatric cystic fibrosis program and services to transition patients from pediatric to adult care.

Advanced research and clinical trials.  The Stanford Adult Cystic Fibrosis Program promotes aggressive advances in the field of cystic fibrosis treatment through data analysis and clinical response focusing on FEV1 improvement, decreased rate of infection, depression, and diabetes risk. Additionally, team physicians have formed a joint collaboration with Infectious Disease and an international cystic fibrosis specialist to develop a standard of care for infection from microbacterium, an increasing problem in cystic fibrosis care. Benefits include:

  • Participation in clinical trials with access to treatments not yet available as standard care, including N-acetylcysteine (NAC)
  • Familiarity with drug protocols well in advance of other facilities due to early research experience and participation in academic clinical trials (e.g., such as with Kalydeco which was recently approved by the FDA)
  • Development of innovative protocols for patient care in accordance with the Cystic Fibrosis Foundation guidelines
  • Genetic analysis for optimal therapy of specific gene mutations
  • Clinical quality improvement groups working on early recognition of diabetes, improving pulmonary function tests, and certain eradication protocols for new organisms

Patient Stories

Stanford senior Molly Pam juggles a demanding daily regimen of drugs and airway-clearing therapies, along with course requirements and her responsibilities as one of the kitchen managers of the Terra House co-op.

Read the full story »


Anabel Stenzel and her twin, Isabel Stenzel-Byrnes, were born with cystic fibrosis. Thanks to the donor families' selfless gifts, and the Stanford Hospital & Clinics Lung Transplant team, the twins now survive and thrive.

Read the full story »
CBS News Coverage »

Stanford Medicine Resources:

Footer Links: